BMRN — BioMarin Pharmaceutical Inc.
8 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about BMRN (2026-11-03)
- BioMarin reported Q3 revenue exceeding $1 billion with 32% YoY growth, beating estimates.
- The company sharply cut its FY26 adjusted EPS guidance to $2.80-$3.10, missing analyst expectations.
| Bluesky | 6 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |
| RSS Bundle | 0 | news |